Trial Profile

Phase IIa Open-label Clinical Study of Intratumoural Administration of BO-112 in Combination With Pembrolizumab in Subjects With Liver Metastasis From Colorectal Cancer or Gastric/Gastro-oesophageal Junction Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 02 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BO 112 (Primary) ; Pembrolizumab (Primary)
Indications Colorectal cancer; Gastric cancer; Liver metastases; Oesophageal cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Highlight Therapeutics

25 Sep 2023 This trial has been discontinued in Spain.
14 Dec 2022 This trial has been discontinued in Belgium according to European Clinical Trials Database record.
14 Dec 2022 This trial has been discontinued in Germany (End Date: 25 Nov 2022) according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com